Population-Native
Our dataset is built on West and Central African phenotypes, the most underrepresented cohort in existing SCD research globally. Every model, every threshold is calibrated here.
Research
The most comprehensive SCD dataset in Africa, built from the ground up.
Real-world, continuous biomarker data from sickle cell patients across Africa. Collected at the community level, not just at the hospital bed.
Built where 75% of the world's SCD patients live.
99% of SCD data comes from hospital visits. Our patients spend 99% of their lives outside hospitals. That's the gap we're closing.
75%
of global SCD burden in sub-Saharan Africa
5
continuous biomarker streams per patient
24/7
real-world monitoring outside hospital walls
1
active academic research partnership
The data advantage
What makes CellGuard data unique
Continuous & Real-World
Not episodic hospital data. Continuous SpO₂, HRV, temperature, hydration, and activity, captured daily, at home, in rural and urban communities across the continent.
Multi-Modal
Wearable vitals + patient-reported outcomes + jaundice visual severity scores + voice symptom logs. No comparable multi-modal SCD dataset exists for Africa.
Longitudinal by Design
Crisis events, prodromal patterns, post-crisis recovery, all timestamped and linked to individual patient histories.
Research platform
Capabilities for partners
Real-World Evidence Generation
Aggregate anonymised cohort data for drug efficacy studies, hydroxyurea adherence outcomes, VOC frequency over time, and mortality proxies.
Clinical Trial Recruitment
Access to a verified, consented SCD patient network across Africa. Filter by genotype (HbSS, HbSC, HbSβ-thalassemia), age, crisis frequency, and medication history.
Remote Patient Monitoring for Trials
Our wearable + app infrastructure is the trial infrastructure, pharma companies don't need to build their own. Plug-and-play remote monitoring for SCD interventional trials.
Biomarker Validation
Validate new crisis-prediction biomarkers against our continuous longitudinal dataset. Particularly valuable for pipeline drugs targeting vaso-occlusive crises.
Study tracker
Featured studies & publications
In Progresswith Nile University of Nigeria
Predicting Vaso-Occlusive Crises in African SCD Patients Using Continuous Wearable Biomarkers and ML
Target: ASH Annual Meeting 2026
Crisis predictionWearable biomarkersOffline-first data collection
In Progress
Scleral Icterus Detection via Smartphone Camera in Dark-Pigmented Skin: Validation Study
Target: APASL / regional conference
Computer visionJaundice proxyAfrican phenotypes
Planned
Hydroxyurea Adherence and Crisis Frequency in African Adolescents: A 12-Month Remote Monitoring Study
Target: TBC
Medication adherencePediatric SCDRural health access
Collaborations
Research built with institutions, not in isolation
CellGuard partners with universities, teaching hospitals, and clinical teams across Africa to produce evidence that reflects how sickle cell is actually lived, outside the ward, in real communities.
Current collaboration
Nile University of Nigeria
Collaborative research on continuous wearable biomarkers and crisis-risk prediction.
Partnership scope
- Academic co-investigation and peer-reviewed publication
- Teaching hospital and hematology unit pilot sites
- Community engagement through patient advocates
- Industry-sponsored trial and monitoring infrastructure
For pharma & biotech
Trial infrastructure where SCD lives
CellGuard operates a continuous wearable monitoring network for SCD patients across Africa. If your pipeline includes VOC prophylaxis, hemolytic agents, or pain management therapies, your clinical trial needs this infrastructure.
- Patient recruitment from verified, consented SCD cohorts
- Regulatory-ready data export with documented quality processes
- On-the-ground research coordination across West and Central Africa
- Ethics board connections through partner institutions
Data ethics & privacy
A framework pharma and patients can trust
NDPR compliance
Full alignment with Nigeria Data Protection Regulation and applicable African data protection frameworks.
Granular consent
Per-study consent, patients choose exactly what they share and can withdraw at any time.
De-identification protocol
Structured de-identification before any research use. Individual patients are never exposed in outputs.
Data sovereignty
No raw patient data leaves Africa without aggregation. Research datasets are built for purpose, not export.
IRB / ethics approval
Every study runs through institutional ethics review, partner HRECs and independent boards as required.
Community science
Every warrior who consents advances the science
Every CellGuard user who opts into research is contributing to the largest African SCD dataset ever built. You're not just managing your health, you're advancing the science for every warrior who comes after you.
Join the pioneer waitlist